

Michael Soyka

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2391677/michael-soyka-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,742
citations

25
h-index

51
g-index

89
ext. papers

3,385
ext. citations

5.8
avg, IF

5.9
L-index

#	Paper	IF	Citations
85	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021 , 116, 106-115	0.7	7
84	Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review. <i>Frontiers in Pharmacology</i> , 2021 , 12, 718811	5.6	1
83	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
82	A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. <i>Liver International</i> , 2021 , 41, 2139-2148	7.9	0
81	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021 , 73, 1920-1931	11.2	18
80	Pharmakologische Rückfallprophylaxe der Alkoholabhängigkeit. <i>Nervenheilkunde</i> , 2021 , 40, 628-635	0.3	
79	Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series. <i>American Journal of Drug and Alcohol Abuse</i> , 2021 , 47, 599-604	3.7	2
78	Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. <i>World Journal of Psychiatry</i> , 2021 , 11, 543-552	3	
77	Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 771126	5	0
76	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020 , 159, 1276-1289.e7	13.3	19
75	Pharmacotherapy of Alcohol Use Disorders 2020 , 1-17		
74	Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts. <i>Frontiers in Psychiatry</i> , 2020 , 11, 592199	5	4
73	Short-term changes in global methylation and hydroxymethylation during alcohol detoxification. <i>European Neuropsychopharmacology</i> , 2019 , 29, 897-903	1.2	4
72	Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. <i>European Psychiatry</i> , 2019 , 59, 15-24	6	21
71	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019 , 68, 1099-1107	19.2	62
70	Pain management in opioid maintenance treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1993-2005	6	6
69	Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. <i>CNS Drugs</i> , 2019 , 33, 649-657	6.7	4

68	Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinence. <i>Psychiatry Research</i> , 2019 , 281, 112599	9.9	9
67	Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. <i>Neuropsychopharmacology</i> , 2019 , 44, 660-667	8.7	19
66	Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence?. <i>Pharmacopsychiatry</i> , 2018 , 51, 243-250	2	19
65	Genome-wide association study identifies inversion in the locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. <i>Gut</i> , 2018 , 67, 1855-1863	19.2	54
64	Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 815-824	27.4	205
63	Baclofen for alcohol use disorder. <i>The Cochrane Library</i> , 2018 , 11, CD012557	5.2	23
62	The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent Individuals. <i>European Addiction Research</i> , 2018 , 24, 255-265	4.6	4
61	Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users. <i>Psychopharmacology</i> , 2018 , 235, 3451-3464	4.7	23
60	Treatment of Benzodiazepine Dependence. <i>New England Journal of Medicine</i> , 2017 , 376, 1147-1157	59.2	156
59	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1987-1999	4	67
58	Pharmacotherapy of alcoholism - an update on approved and off-label medications. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1187-1199	4	60
57	Treatment of opioid dependence with buprenorphine: current update. <i>Dialogues in Clinical Neuroscience</i> , 2017 , 19, 299-308	5.7	12
56	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. <i>Behavior Genetics</i> , 2016 , 46, 151-69	3.2	77
55	Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 70, 148-61	5.5	23
54	Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 619-26	4	28
53	Abstinence or maintenance treatment in substance use disorders?. <i>Addiction</i> , 2016 , 111, 775-6	4.6	4
52	Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. <i>European Addiction Research</i> , 2015 , 21, 78-87	4.6	48
51	Serotonin and Dopamine Candidate Gene Variants and Alcohol- and Non-Alcohol-Related Aggression. <i>Alcohol and Alcoholism</i> , 2015 , 50, 690-9	3.5	8

50	XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide gene-set-based analysis and follow-up studies in <i>Drosophila</i> and humans. <i>Neuropsychopharmacology</i> , 2015 , 40, 361-71	8.7	12
49	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. <i>Nature Genetics</i> , 2015 , 47, 1443-8	36.3	303
48	Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 339-47	8	4
47	Val158Met COMT polymorphism and risk of aggression in alcohol dependence. <i>Addiction Biology</i> , 2015 , 20, 197-204	4.6	10
46	New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. <i>Substance Abuse and Rehabilitation</i> , 2015 , 6, 1-14	5.5	34
45	A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. <i>Journal of Hepatology</i> , 2014 , 61, 1073-9	13.4	28
44	Nalmefene for the treatment of alcohol dependence: a current update. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 675-84	5.8	25
43	Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. <i>American Journal on Addictions</i> , 2014 , 23, 563-9	3.7	8
42	Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy. <i>Addiction</i> , 2014 , 109, 88-9	4.6	1
41	Buprenorphine use in pregnant opioid users: a critical review. <i>CNS Drugs</i> , 2013 , 27, 653-62	6.7	17
40	Buprenorphine and buprenorphine/naloxone intoxication in children - how strong is the risk?. <i>Current Drug Abuse Reviews</i> , 2013 , 6, 63-70		6
39	Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. <i>Journal of Forensic Sciences</i> , 2012 , 57, 1524-30	1.8	20
38	Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. <i>Expert Opinion on Drug Delivery</i> , 2012 , 9, 1409-17	8	8
37	Prevalence of delusional jealousy in psychiatric disorders. <i>Journal of Forensic Sciences</i> , 2011 , 56, 450-2	1.8	14
36	A comparison of cognitive function in patients under maintenance treatment with heroin, methadone, or buprenorphine and healthy controls: an open pilot study. <i>American Journal of Drug and Alcohol Abuse</i> , 2011 , 37, 497-508	3.7	24
35	Neurobiology of aggression and violence in schizophrenia. <i>Schizophrenia Bulletin</i> , 2011 , 37, 913-20	1.3	78
34	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 160-87	3.8	73
33	To substitute or not substitute optimal tactics for the management of benzodiazepine dependence. <i>Addiction</i> , 2010 , 105, 1876-7	4.6	7

32	Cognitive function in short- and long-term substitution treatment: Are there differences?. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 400-408	3.8	19
31	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , 2010 , CD004332	5.2	160
30	Why should addiction medicine be an attractive field for young physicians?. <i>Addiction</i> , 2009 , 104, 169-72	4.6	16
29	FURTHER REFLECTIONS ON WHY SHOULD ADDICTION MEDICINE BE AN ATTRACTIVE FIELD FOR YOUNG PHYSICIANS? <i>Addiction</i> , 2009 , 104, 177-178	4.6	
28	Feasibility and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 217-24	3.8	8
27	Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 317-24	1.7	92
26	Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 641-53	5.8	111
25	Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 699-703	1.7	56
24	One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 657-60	1.7	46
23	Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 395-401	5.1	16
22	Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 490-3	1.7	45
21	Thalamic hypofunction in alcohol hallucinosis: FDG PET findings. <i>Psychiatry Research - Neuroimaging</i> , 2005 , 139, 259-62	2.9	15
20	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005 , 39, 101-8	5.2	39
19	Driving ability in schizophrenic patients: effects of neuroleptics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005 , 9, 168-74	2.4	5
18	Outpatient alcohol detoxification: implementation efficacy and outcome effectiveness of a model project. <i>European Addiction Research</i> , 2004 , 10, 180-7	4.6	16
17	Delinquency and criminal offenses in former schizophrenic inpatients 7-12 years following discharge. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 289-94	5.1	26
16	Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. <i>American Journal on Addictions</i> , 2003 , 12, s69-s80	3.7	23
15	Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. <i>European Addiction Research</i> , 2003 , 9, 65-72	4.6	26

14	A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002 , 252, 197-200	5.1	18
13	Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. <i>Drugs in R and D</i> , 2002 , 3, 1-12	3.4	19
12	Psychopathology in dual diagnosis and non-addicted schizophrenics--are there differences?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 232-8	5.1	42
11	Psychomotor Performance Under Neuroleptic Treatment in Schizophrenia. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2001 , 12, 49-53	0.5	6
10	PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 215-8	3.8	14
9	Substance misuse, psychiatric disorder and violent and disturbed behaviour. <i>British Journal of Psychiatry</i> , 2000 , 176, 345-50	5.4	203
8	Pharmacotherapies of Opioid Detoxification—An Evaluation of Different Pharmacotherapeutical Strategies. <i>Alcoholism Treatment Quarterly</i> , 1999 , 17, 47-53	1.2	
7	Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. <i>CNS Drugs</i> , 1997 , 7, 313-27	6.7	19
6	Pharmacological trials in alcoholics—Some comments on methodological problems. <i>Addiction</i> , 1997 , 92, 956-958	4.6	2
5	Propofol dependency. <i>Addiction</i> , 1997 , 92, 1369-1370	4.6	2
4	Dual Diagnosis in Patients with Schizophrenia. <i>CNS Drugs</i> , 1996 , 5, 414-425	6.7	15
3	Pathophysiological mechanisms possibly involved in the development of alcohol hallucinosis. <i>Addiction</i> , 1995 , 90, 289-290	4.6	
2	Substance abuse in schizophrenics. <i>British Journal of Psychiatry</i> , 1994 , 165, 836-7	5.4	
1	L-dopa abuse in a patient with former alcoholism. <i>Addiction</i> , 1992 , 87, 117-8	4.6	12